UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 01/2018, Volume 2018, Issue 1, pp. CD009669 - CD009669
Simendan | C.1 Drugs | Dobutamine | Hydrazones | Nitric Oxide | Cardiac Output, Low | Cause of Death | Randomized Controlled Trials as Topic | Cardiotonic Agents | Pyridazines | Vasodilator Agents | Myocardial ischemia/coronary disease | Myocardial Infarction | Enoximone | C.1.10 Other | C. Acute Coronary Syndromes/Unstable Angina | Shock, Cardiogenic | Heart & circulation | Medicine General & Introductory Medical Sciences | Acute coronary syndrome | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Myocardial Infarction - mortality | Vasodilator Agents - therapeutic use | Humans | Middle Aged | Shock, Cardiogenic - mortality | Nitric Oxide - therapeutic use | Cardiac Output, Low - etiology | Cardiotonic Agents - therapeutic use | Myocardial Infarction - complications | Shock, Cardiogenic - drug therapy | Shock, Cardiogenic - etiology | Enoximone - therapeutic use | Cardiac Output, Low - mortality | Hydrazones - therapeutic use | Aged | Cardiac Output, Low - drug therapy | Dobutamine - therapeutic use | Pyridazines - therapeutic use | Index Medicus
Journal Article
Cell reports (Cambridge), ISSN 2211-1247, 05/2017, Volume 19, Issue 8, pp. 1669 - 1684
lung cancer | histone methylation | taxane-platin chemotherapy | JIB-04 | GSK-J4 | KDM | histone demethylases | demethylase inhibitors | Jumonji demethylases | drug resistance | Life Sciences & Biomedicine | Science & Technology | Cell Biology | Lung Neoplasms - drug therapy | Transcription, Genetic - drug effects | Taxoids - pharmacology | Benzazepines - adverse effects | Humans | Aminopyridines - adverse effects | Lung Neoplasms - pathology | Antineoplastic Agents - therapeutic use | Gene Expression Profiling | Taxoids - therapeutic use | Hydrazones - adverse effects | Aminopyridines - therapeutic use | Carboplatin - therapeutic use | Hydrazones - therapeutic use | Jumonji Domain-Containing Histone Demethylases - antagonists & inhibitors | Bridged-Ring Compounds - pharmacology | Neoadjuvant Therapy | Antineoplastic Agents - pharmacology | Gene Expression Regulation, Neoplastic - drug effects | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Bridged-Ring Compounds - therapeutic use | Carcinoma, Non-Small-Cell Lung - genetics | Enzyme Inhibitors - pharmacology | Benzazepines - pharmacology | Pyrimidines - pharmacology | Enzyme Inhibitors - therapeutic use | Hydrazones - pharmacology | Disease-Free Survival | Drug Resistance, Neoplasm - genetics | Animals | Benzazepines - therapeutic use | Pyrimidines - therapeutic use | Aminopyridines - pharmacology | Pyrimidines - adverse effects | Cell Line, Tumor | Mice | Carcinoma, Non-Small-Cell Lung - drug therapy | Histones - metabolism | Carboplatin - pharmacology | Methylation | Jumonji Domain-Containing Histone Demethylases - metabolism | Drug Resistance, Neoplasm - drug effects | Index Medicus
Journal Article
Journal of critical care, ISSN 0883-9441, 2016, Volume 37, pp. 91 - 98
Critical Care | Microcirculation | Sepsis | Vasopressors | Inotropes | Intensive care | Mortality | Life Sciences & Biomedicine | Critical Care Medicine | General & Internal Medicine | Science & Technology | Arginine Vasopressin - therapeutic use | Dopamine - therapeutic use | Vasoconstrictor Agents - therapeutic use | Norepinephrine - therapeutic use | Vasopressins - therapeutic use | Humans | Treatment Outcome | Shock, Septic - mortality | Randomized Controlled Trials as Topic | Sepsis - mortality | Cardiotonic Agents - therapeutic use | Sepsis - drug therapy | Epinephrine - therapeutic use | Hydrazones - therapeutic use | Shock, Septic - drug therapy | Network Meta-Analysis | Odds Ratio | Dobutamine - therapeutic use | Pyridazines - therapeutic use | Septic shock | Analysis | Patient outcomes | Epinephrine | Medical research | Cardiac patients | Medicine, Experimental | Index Medicus
Journal Article
Nature reviews cardiology, ISSN 1759-5002, 02/2013, Volume 10, Issue 2, pp. 85 - 97
Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Natriuretic Peptide, Brain - therapeutic use | Patient Readmission | Risk Assessment | Humans | Risk Factors | Treatment Outcome | Xanthines - therapeutic use | Evidence-Based Medicine | Heart Failure - drug therapy | Patient Selection | Cardiovascular Agents - therapeutic use | Clinical Trials, Phase III as Topic | Animals | Time Factors | Benzazepines - therapeutic use | Hydrazones - therapeutic use | Tetrazoles - therapeutic use | Heart Failure - diagnosis | Cardiovascular Agents - adverse effects | Pyridazines - therapeutic use | Clinical Trials, Phase II as Topic | Heart Failure - mortality | Pyridines - therapeutic use | Heart failure | Clinical trials | Product development | Dosage and administration | Management | Drug therapy | Cardiovascular agents | Index Medicus
Journal Article
Cochrane database of systematic reviews, ISSN 1469-493X, 2014, Volume 1, Issue 1, pp. CD009669 - 70
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Simendan | Vasodilator Agents - therapeutic use | Humans | Nitric Oxide - therapeutic use | Randomized Controlled Trials as Topic | Cardiac Output, Low - etiology | Cardiotonic Agents - therapeutic use | Myocardial Infarction - complications | Shock, Cardiogenic - drug therapy | Shock, Cardiogenic - etiology | Enoximone - therapeutic use | Hydrazones - therapeutic use | Cardiac Output, Low - drug therapy | Dobutamine - therapeutic use | Pyridazines - therapeutic use | Index Medicus
Journal Article